Data presented at the American Society of Clinical Oncology (ASCO) reinforce enthusiasm for a new approach being developed by companies including Elevation Oncology (Nasdaq: ELEV).
Results from an early-stage study of the firm's anti-Claudin18.2 candidate EO-3021 reveal a well-tolerated safety profile for people with difficult to treat cancers.
Elevation is following in the footsteps of Japanese drug major Astellas Pharma (TYO: 4503)
https://www.thepharmaletter.com/article/elevation-s-asco-data-validate-work-on-novel-cancer-target
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.